Somatropin
Recombinant human growth hormone — the full 191-amino-acid pituitary peptide, FDA-approved for a short list of specific deficiency and wasting indications and the subject of an enormous off-label market for anti-aging, performance, and body-composition use that runs far ahead of the evidence.
What is Somatropin?
Somatropin is recombinant human growth hormone (rhGH) — a bioidentical copy of the endogenous 191-amino-acid peptide secreted by somatotroph cells of the anterior pituitary. It is produced in E. coli or mammalian expression systems and supplied as a lyophilized or liquid preparation for subcutaneous or intramuscular injection. Multiple manufacturers market identical or near-identical products under different brand names (Genotropin, Humatrope, Norditropin, Saizen, Nutropin, Omnitrope, Zomacton). Serostim is a distinct product licensed specifically for HIV-associated wasting. Somatropin acts primarily through the GH receptor on liver and peripheral tissues, driving hepatic IGF-1 production and a constellation of anabolic, lipolytic, and counter-regulatory metabolic effects.
What Somatropin Is Investigated For
Somatropin is one of the most thoroughly studied peptides in clinical medicine for its approved indications and one of the most over-hyped in its unapproved ones. For pediatric and adult growth hormone deficiency, Turner syndrome, Prader-Willi, SGA short stature, and HIV-associated wasting, the evidence base is decades deep and the benefit is real. Outside those frames — for healthy-adult anti-aging, body composition, or athletic performance — the evidence is much thinner than the marketing suggests. Rudman's 1990 NEJM trial lit the spark that launched an entire industry, but the follow-up literature (Liu 2007, 2008) found small lean-mass gains, no meaningful strength improvement, and a substantial side-effect burden. Almost all non-prescription rhGH use in the US is illegal under the Anti-Drug Abuse Act of 1990, and rhGH sourced outside the pharmaceutical supply chain carries real risks of adulteration, underdosing, or impurity. If you landed on this page researching rhGH as a wellness tool, the honest frame is that it is a prescription hormone with specific indications, a real adverse-event profile, and a long history of overselling.
History & Discovery
Growth hormone was isolated from pituitary glands in the 1940s–1950s, with Choh Hao Li at UC Berkeley characterizing the human form in the 1960s. For its first therapeutic decades it was available only as cadaver-derived pituitary GH — a supply so scarce that treatment was restricted to the most severely affected pediatric GHD patients. The cadaveric program ended abruptly in 1985 when four young adult recipients in the US National Hormone and Pituitary Program were diagnosed with Creutzfeldt-Jakob disease, linked to prion contamination of pituitary harvests. Recombinant human growth hormone, produced in E. coli, was approved by the FDA the same year (Genentech's Protropin, 1985; Eli Lilly's Humatrope, 1987) and immediately replaced cadaveric GH as the standard of care. The 1990 publication of Rudman's twelve-man, six-month rhGH trial in healthy men over 60, reporting a ~9% lean-mass increase and ~14% fat-mass decrease, launched an entire industry. Anti-aging clinics, 'longevity' prescribers, and an illicit supply chain all emerged in the 1990s to serve healthy-adult demand, much of it running ahead of the evidence and much of it illegal under the Anti-Drug Abuse Act of 1990, which Congress passed specifically to criminalize the off-label distribution of rhGH for uses other than FDA-approved indications. The indication list expanded over the next two decades to cover Turner syndrome (1996), Prader-Willi (2000), idiopathic short stature (2003), SHOX deficiency (2006), Noonan syndrome (2007), and others — each requiring its own pivotal trial program. Serostim was approved specifically for HIV-associated wasting in 1996. The SAGhE multinational cohort, launched in the 2000s, has been the principal source of long-term post-marketing safety data for childhood rhGH use.
How It Works
Growth hormone is the body's main anabolic pituitary signal — it tells the liver to make IGF-1, tells fat cells to release fatty acids, and tells muscle and other tissues to take up amino acids and grow. Somatropin is a manufactured copy of the same molecule, injected to restore or supplement what the pituitary produces. In children who don't make enough, it restores normal growth. In adults, it shifts body composition toward more lean mass and less fat — but at doses above physiologic replacement it also raises blood sugar, retains fluid, and causes joint pain.
Somatropin binds the growth hormone receptor (GHR), a class I cytokine receptor that dimerizes on ligand binding and activates JAK2-STAT5 signaling. The major downstream effect is hepatic transcription of IGF-1, which circulates as the dominant mediator of GH's anabolic effects on cartilage, bone, and muscle. GH also has direct receptor-mediated effects at peripheral tissues: lipolysis at adipocytes (via HSL activation and reduced LPL activity), increased hepatic gluconeogenesis, decreased peripheral glucose uptake, and stimulation of renal sodium retention. The combination of direct insulin antagonism at liver and muscle plus IGF-1-mediated anabolic effects produces the characteristic GH pharmacological profile — anabolism in muscle and bone coupled with impaired glucose tolerance. Endogenous GH is secreted in pulses under control of hypothalamic GHRH (stimulatory) and somatostatin (inhibitory), with the largest pulse typically occurring 1–2 hours after sleep onset. Exogenous somatropin delivered once daily does not replicate this pulsatile pattern, which is one of the arguments advocates make for secretagogue-based approaches over direct rhGH administration.
Evidence Snapshot
Human Clinical Evidence
Strong for approved indications — decades of RCTs in pediatric GHD, adult GHD, Turner syndrome, Prader-Willi, SGA, and HIV wasting. Moderate-to-limited for healthy-adult body composition and anti-aging, where the Rudman 1990 NEJM study launched the field but subsequent meta-analyses (Liu 2007, 2008) found modest effects and substantial adverse events.
Animal / Preclinical
Extensive. GH/IGF-1 axis biology is one of the best-characterized in endocrinology, with lifespan-extension observations in GH-receptor-knockout mice (Laron models) that run opposite to the human anti-aging narrative.
Mechanistic Rationale
Strong. GHR signaling, JAK2-STAT5 pathway, hepatic IGF-1 production, and peripheral metabolic effects are thoroughly mapped.
Research Gaps & Open Questions
What the current literature has not yet settled about Somatropin:
- 01Long-term cardiovascular and cancer outcomes of adult rhGH replacement therapy initiated in middle age for partial GHD or borderline cases.
- 02Whether the modest body-composition effects seen with rhGH in healthy older adults translate to any functional benefit (strength, endurance, fall risk, cognition) — existing meta-analyses say no, but the trials are generally short.
- 03Optimal rhGH dosing strategy in adult GHD: once-daily subcutaneous is standard, but pulsatile or secretagogue-based approaches have theoretical appeal and little head-to-head data.
- 04Whether specific subpopulations (women on oral estrogen, patients with elevated baseline IGF-1, those with metabolic syndrome) benefit differently or carry different risk profiles from generic GHD populations.
- 05The risk-benefit of rhGH in post-surgical recovery and injury rehabilitation, a use case with plausible mechanism but limited controlled data outside HIV wasting and severe burn contexts.
- 06Long-term safety in cohorts initiated in adulthood for non-GHD indications — most large safety datasets are pediatric (SAGhE) or specific-disease (Serostim/HIV, KIMS/Pfizer adult GHD).
Forms & Administration
Somatropin is supplied as a lyophilized powder for reconstitution or as a prefilled liquid pen in dose-metered devices (Genotropin Pen, Norditropin FlexPro, Humatrope cartridges, etc.). Administration is subcutaneous — typical sites are thigh, abdomen, or upper arm — with injection sites rotated. Storage requires refrigeration (2–8°C); reconstituted product is typically usable for 14–28 days refrigerated depending on the specific product. rhGH is prescription-only in the US and requires specialty-pharmacy handling for most brands. The compounded-peptide market does not legitimately supply rhGH; research-chemical or 'grey market' rhGH is frequently adulterated, underdosed, or entirely counterfeit, and is a recurrent source of infection and mislabeling incidents.
Dosing & Protocols
The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.
Typical Range
Pediatric GHD: weight-based at 0.16–0.24 mg/kg/week divided daily or 6×/week SC. Adult GHD: start 0.1–0.3 mg/day SC, titrate to IGF-1 at the middle of the age-adjusted reference range. HIV wasting (Serostim): 0.1 mg/kg/day up to 6 mg/day SC. Anti-aging / off-label healthy-adult use typically cites 1–3 IU (roughly 0.33–1.0 mg) daily, but this use pattern is not an approved indication and is not dosed under clinical guidelines.
Frequency
Once daily subcutaneous injection is standard across indications, typically dosed in the evening to loosely approximate the nocturnal GH pulse pattern, though this timing is as much convention as evidence. Some protocols split into 6-days-on, 1-day-off cycles.
Timing Considerations
Time of day
Evening, typically 1–2 hours before bed — loosely mimics the nocturnal endogenous GH pulse, though clinical evidence that evening timing outperforms other timings is modest.
Relative to meals
Not meal-timed in a clinically meaningful sense; some protocols avoid dosing within 30 minutes of a high-carbohydrate meal because of transient insulin-resistance interaction.
Relative to exercise
Not typically exercise-timed. Endogenous GH pulses after resistance exercise, but exogenous dosing is generally uncoupled from training schedule.
Injection-site rotation (thigh, abdomen, upper arm) is the main day-to-day operational detail — repeated injection at the same site predisposes to lipohypertrophy. Morning dosing is also acceptable and is preferred in some pediatric protocols for compliance.
Cycle Length
Pediatric and adult GHD treatment is continuous until final height is reached (pediatric) or indefinitely for adult replacement. Anti-aging / off-label cycles often run 3–6 months followed by a break, but these are self-directed patterns rather than evidence-based protocols.
Protocol Notes
Reconstituted rhGH requires refrigeration and has limited stability once mixed — typically 14–28 days depending on product. Dose titration in adult GHD is guided by IGF-1 levels and tolerability: fluid retention, arthralgia, and glucose elevation are the usual dose-limiting side effects. For pediatric patients, growth velocity is monitored and the dose adjusted to keep IGF-1 in the upper half of the age-adjusted range. Interchanging brands mid-course is not routine — immunogenicity concerns, dose-pen mechanics, and pharmacokinetic differences are brand-specific. For any use framed as anti-aging or performance-enhancing in a healthy adult, the central clinical reality is that this is not an approved indication, is illegal to distribute in the US outside the pharmaceutical supply chain, and is not what the evidence base supports. The published dose ranges for such use are drawn from grey literature and self-reports rather than controlled trials.
Somatropin is a prescription medication. Non-prescription use is illegal under US federal law (21 USC 333(e)). Nothing on this page constitutes a suggested off-label protocol. Patients with symptoms of growth hormone deficiency should consult an endocrinologist.
Timeline of Effects
Onset
Effects on fluid balance and a subjective sense of well-being can emerge within the first week of therapy. IGF-1 rises within 24–48 hours of dosing and stabilizes at a new steady-state within 1–2 weeks. Body-composition changes are slower: measurable lean-mass and fat-mass shifts typically require 8–12 weeks of continuous dosing to become statistically detectable at group level, and individual responses vary widely.
Peak Effect
In pediatric GHD, peak growth velocity is typically seen in the first treatment year, with attenuation thereafter. In adult replacement, IGF-1 normalization and the majority of body-composition effects are seen within 3–6 months. In anti-aging-style off-label use, reported subjective effects peak within the first 2–3 months — coinciding with fluid shifts and insulin-resistance changes — and plateau thereafter.
After Discontinuation
IGF-1 declines to baseline within 1–2 weeks of discontinuation. Body-composition changes partly reverse over 2–6 months without ongoing therapy. Fluid-retention and side-effect symptoms resolve within days. There is no classical withdrawal syndrome from rhGH, but patients with adult GHD who discontinue will revert to their pre-treatment symptom profile (adiposity, low energy, reduced exercise capacity).
Monitoring & Measurement
Bloodwork & Labs
- •IGF-1 (primary response marker; target mid-range of age-adjusted reference in adult replacement)
- •IGFBP-3 (adjunct to IGF-1, particularly in pediatric monitoring)
- •Fasting glucose and HbA1c (rhGH impairs insulin sensitivity)
- •Free T4 (rhGH can unmask central hypothyroidism)
- •Morning cortisol (rhGH can unmask central adrenal insufficiency)
- •Lipid panel (modest favorable shifts expected in adult GHD replacement)
Functional & Performance Tests
- •DEXA body composition — the gold-standard measurement of the lean-mass and fat-mass shifts rhGH is dosed to produce
- •Height velocity (pediatric) — primary endpoint in pediatric GHD and short-stature indications
- •Hand-grip strength and timed physical performance (adult GHD trials)
When to Test
Baseline before initiation. IGF-1 and tolerability assessment at 4–8 weeks, then every 3–6 months during stable therapy. Metabolic panel and thyroid/adrenal axis annually or if symptoms emerge. Pediatric patients are typically seen every 3 months for growth velocity and annually for bone age.
Interpretation & Notes
IGF-1 is the workhorse marker — it is relatively stable across the day (unlike GH itself, which is pulsatile), reflects steady-state exposure, and maps onto both efficacy and safety. A target of mid-range age-adjusted IGF-1 is the standard titration endpoint in adult GHD. Levels consistently above the upper reference limit raise concern for over-replacement and warrant dose reduction. For patients being evaluated for possible GHD, the diagnostic workup requires dynamic stimulation testing (insulin tolerance test, glucagon stimulation test, or macimorelin) rather than baseline GH or IGF-1 alone, because endogenous GH is pulsatile and a single level is uninformative.
Common Questions
Who Somatropin Is NOT For
- •Active malignancy — rhGH is contraindicated in patients with ongoing cancer treatment and historically has been considered contraindicated in patients with active tumors.
- •Critical illness following open-heart or abdominal surgery, multiple accidental trauma, or acute respiratory failure — a 1999 ICU trial showed excess mortality with high-dose rhGH in acutely ill patients.
- •Active proliferative or severe non-proliferative diabetic retinopathy.
- •Closed epiphyses in patients being treated for short stature (pediatric-specific).
- •Known hypersensitivity to somatropin or any excipient in the specific formulation.
- •Prader-Willi patients who are severely obese, have severe respiratory impairment, or have untreated sleep apnea — fatal respiratory events have been reported.
- •Active or uncontrolled intracranial tumor (in patients for whom rhGH is being considered post-CNS-tumor remission, reassessment is required).
Drug & Supplement Interactions
Somatropin interacts meaningfully with several drug classes, most via its metabolic or endocrine effects rather than direct pharmacokinetic interactions. Insulin and oral antihyperglycemic requirements often rise because rhGH impairs insulin sensitivity — diabetic patients starting rhGH routinely require dose adjustments. Glucocorticoids at replacement doses may need uptitration because rhGH enhances 11β-HSD2 activity and can accelerate cortisol clearance; conversely, starting rhGH in a patient on the edge of adrenal insufficiency can unmask the condition. Levothyroxine requirements sometimes rise because rhGH accelerates T4-to-T3 conversion, lowering free T4; patients should have thyroid function monitored after initiation. Oral estrogen (but not transdermal) reduces rhGH responsiveness by suppressing IGF-1 generation, so women on oral estrogen therapy often require higher somatropin doses. CYP450 substrates with narrow therapeutic indices (cyclosporine, warfarin, anticonvulsants) may require monitoring because rhGH can modestly alter hepatic P450 activity. Concurrent GLP-1 agonist use does not appear to meaningfully affect rhGH pharmacology but may offset some of its insulin-resistance effect.
Safety Profile
Common Side Effects
Cautions
- • Increased risk of unmasking latent or worsening active malignancy — rhGH is contraindicated in patients with active cancer
- • Can unmask central hypothyroidism and central adrenal insufficiency — free T4 and morning cortisol should be monitored
- • Insulin and oral antihyperglycemic requirements often rise
- • Benign intracranial hypertension has been reported, particularly in pediatric initiations
- • Risk of slipped capital femoral epiphysis in pediatric patients
- • Long-term SAGhE cohort data show modestly elevated all-cause and cerebrovascular mortality in treated childhood cohorts — interpretation is debated but the signal is not zero
What We Don't Know
The long-term consequences of continuous adult rhGH therapy initiated for anti-aging indications are not well characterized, because the largest prospective cohorts were assembled for pediatric and adult-GHD replacement, not for healthy-adult supplementation. Whether the modest body-composition effects in healthy adults translate to functional benefit is contested, and whether long-term exposure raises cancer incidence in treated adults remains an open question with conflicting signal from observational data.
Legal Status
United States
Prescription-only. Somatropin is FDA-approved for pediatric GHD, adult GHD, Turner syndrome, Prader-Willi syndrome, SGA short stature, idiopathic short stature, SHOX deficiency, Noonan syndrome, chronic renal insufficiency in pediatric patients, and HIV-associated wasting (Serostim). Non-prescription distribution for any other purpose — including anti-aging or athletic performance — is a felony under the Anti-Drug Abuse Act of 1990 (21 USC 333(e)). The DEA and state medical boards have pursued actions against prescribers operating in the anti-aging market.
International
Approved as a prescription medicine across the EU, UK, Canada, Australia, and most major markets under the same or similar indication lists. Brand portfolios differ by region. Non-prescription distribution is restricted in most jurisdictions but specific enforcement and availability vary.
Sports & Competition
Explicitly banned under WADA's S2 class (peptide hormones, growth factors, related substances and mimetics), prohibited at all times both in- and out-of-competition. Detection is by the isoform-ratio test (~24–48 h window) and biomarker test (up to 2-week window). rhGH use has produced positive tests at Olympic, professional, and collegiate levels.
Regulatory status changes over time. Verify current local rules with a qualified professional.
Myths & Misconceptions
Myth
rhGH is a proven anti-aging therapy backed by solid evidence.
Reality
Rudman 1990 showed modest 6-month body-composition shifts in a dozen healthy elderly men. The Liu 2007 Annals meta-analysis of 31 subsequent trials concluded that rhGH in healthy elderly adults produces small lean-mass increases (mostly fluid), no functional-strength benefit, and a meaningful side-effect burden. 'Anti-aging rhGH' is a marketing category, not an evidence-backed indication.
Myth
Because HGH is bioidentical to the body's own hormone, it's safe.
Reality
Bioidentical is not the same as physiologic. Endogenous GH is secreted in pulses at weight- and age-appropriate levels; exogenous rhGH delivers supraphysiologic steady-state exposure. Supraphysiologic GH exposure is the mechanism of acromegaly — fluid retention, cardiomegaly, insulin resistance, arthropathy, and increased cardiovascular mortality — and those same mechanisms operate at lower intensity with high-dose rhGH.
Myth
You can buy real HGH online legally for personal use.
Reality
In the United States, distributing rhGH for any use other than an FDA-approved indication is a felony under the Anti-Drug Abuse Act of 1990. Products sold online outside the pharmacy supply chain are frequently counterfeit, underdosed, or contaminated. Grey-market 'HGH' is a recurrent source of infection and mislabeling cases — independent testing has repeatedly found zero active ingredient or substitution with other compounds.
Myth
rhGH and GH secretagogues like sermorelin or CJC-1295 are interchangeable.
Reality
Secretagogues act on the pituitary to release endogenous GH in a pulsatile pattern under intact negative feedback. rhGH delivers exogenous hormone at whatever dose is injected, with no feedback regulation. The two have different pharmacokinetics, different side-effect profiles, and different regulatory status. They are not clinically interchangeable.
Myth
rhGH builds significant muscle and strength.
Reality
Controlled trials in healthy adults show small lean-mass gains that are largely fluid — water of hydration in the muscle rather than contractile protein. The Liu 2008 meta-analysis found no reliable improvement in strength, power, or aerobic capacity. The compelling anecdotes in bodybuilding culture are heavily confounded by concurrent anabolic steroid use; rhGH as a monotherapy for strength and hypertrophy does not match the hype.
Published Research
10 studiesLong-term mortality in patients treated with recombinant growth hormone for isolated growth hormone deficiency or idiopathic short stature in the SAGhE cohort
SAGhE long-term mortality follow-up — found no excess all-cause mortality in low-risk childhood rhGH cohorts, partly reassuring against earlier French SAGhE signals. Part of the ongoing post-marketing safety picture.
Cancer risks in patients treated with growth hormone in childhood: the SAGhE European cohort study
SAGhE 2017 — the largest multi-European cohort study of childhood rhGH treatment, reporting no overall cancer-incidence increase but elevated risk for specific second malignancies in subpopulations. A central source for long-term rhGH safety analysis.
The Safety and Appropriateness of Growth Hormone Treatments in Europe (SAGhE) — study design and population
Foundational description of the SAGhE multinational post-marketing surveillance cohort on which most contemporary long-term rhGH safety conclusions rest.
GH/IGF-1 replacement therapy in adults with Prader-Willi syndrome
Deal 2013 — consensus guidelines on rhGH use in Prader-Willi syndrome, covering body-composition and respiratory-safety considerations that shape pediatric and adult practice.
Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline
Molitch 2011 — the Endocrine Society's clinical practice guideline for adult GHD, covering diagnostic stimulation testing, starting-dose strategies, and safety monitoring. The reference standard for adult GHD replacement.
The detection of growth hormone abuse in sport
Holt 2009 — review of the WADA isoform-ratio and biomarker tests for rhGH doping detection, including the scientific basis of detection windows and evasion strategies seen in practice.
Systematic review: the effects of growth hormone on athletic performance
Liu 2008 Annals of Internal Medicine — the parallel meta-analysis on athletic performance, finding no reliable improvement in strength, power, or aerobic capacity despite modest lean-mass gains largely attributable to fluid retention.
Systematic review: the safety and efficacy of growth hormone in the healthy elderly
Liu 2007 Annals of Internal Medicine — meta-analysis of 31 studies concluding that rhGH in healthy elderly adults produces small lean-mass increases without strength or functional benefit, paired with high rates of adverse events. The most-cited critical assessment of the anti-aging use case.
Recombinant human growth hormone in patients with HIV-associated wasting
Schambelan 1996 Annals of Internal Medicine — pivotal trial supporting rhGH (later marketed as Serostim) for HIV-associated wasting, establishing the indication that remains approved today.
Effects of human growth hormone in men over 60 years old
Rudman 1990 NEJM — the original six-month trial that launched the rhGH anti-aging industry, showing increased lean mass and decreased adiposity in men aged 61–81. Subsequent follow-up and replication have tempered the original interpretation.
Quick Facts
- Class
- Pituitary Hormone
- Evidence
- Strong
- Safety
- Well-Studied
- Updated
- Apr 2026
- Citations
- 10PubMed
Also known as
Tags
Evidence Score
Clinical Trials
View Clinical TrialsLinks to ClinicalTrials.gov for reference. Listing does not imply endorsement.